… Valganciclovir (VGCV) is a prodrug of GCV with improved … treatment to oral GCV w7x for
treatment of neonates. We present a neonate with congenital CMV infection, who was treated …

… one third of patients as part of the natural history of this disease, prospective, controlled
trial designs are critical to assess treatment benefit in patients with congenital CMV infections. …

… The main side effect of treatment was transient neutropenia. In conclusion, prolonged …
congenital CMV infection with intravenous ganciclovir followed by oral valganciclovir is safe, and it …

… asymptomatic CMV infection and consecutive fetal CMV infection confirmed by high CMV
VL in AF. Serologic findings in the first trimester hinted at a primary CMV infection. The first …

… CMV infection (40,000 infants/year) [6]. Of … valganciclovir after administration of intravenous
ganciclovir in version 2.0 of the study, 15 study subjects restarted valganciclovir treatment at …

… , valganciclovir appears to have some advantages over ganciclovir. Therefore, when used as
prophylaxis against CMV infection … of CMV retinitis in patients with AIDS, oral valganciclovir …

… of CMV infection and disease were used (23). Asymptomatic CMV infection was defined
as the detection of CMV … Episodes of CMV DNAemia separated by at least two consecutive …

… Since then, three additional systemic antiviral agents have been approved for use in the
US: valganciclovir (VGCV), the oral prodrug of GCV, foscarnet (FOS), and cidofovir (CDV) (Table …

… valganciclovir is absorbed vs 6% to 9% of oral ganciclovir. Plasma levels of oral valganciclovir
… the first report of successful treatment of cutaneous CMV infection with an oral medication. …

… the effectiveness of ganciclovir and valganciclovir in preventing CMV disease in a …
valganciclovir-treated patients developed CMV infection as opposed to 2/20 (10%) …